We are live on
!
Find out more
GFM
GF Fund Management Portfolio holdings
AUM
$5.98B
1-Year Est. Return
80.99%
This Fund
S&P 500
This Quarter
Est. Return
+7.58%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.56B
Cap. Flow
% of AUM
98.7%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$400M |
| 2 |
Apple
AAPL
|
+$352M |
| 3 |
Microsoft
MSFT
|
+$326M |
| 4 |
Amazon
AMZN
|
+$218M |
| 5 |
Meta Platforms (Facebook)
META
|
+$195M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 45.41% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Evolus
EOLS
$397M
| $14.7K | ﹤0.01% |
+1,330
| New | +$18.7K |
|
502
Relay Therapeutics
RLAY
$4B
| $14.5K | ﹤0.01% |
+3,515
| New | +$19.1K |
|
|
TECX
503
Tectonic Therapeutic
TECX
$536M
| $14.3K | ﹤0.01% |
+310
| New | +$13.1K |
|
|
ORKA
504
Oruka Therapeutics
ORKA
$5.31B
| $14.3K | ﹤0.01% |
+735
| New | +$17.9K |
|
505
Kura Oncology
KURA
$793M
| $14.2K | ﹤0.01% |
+1,633
| New | +$23.5K |
|
|
CRGX
506
DELISTED
CARGO Therapeutics
CRGX
| $13.9K | ﹤0.01% |
+966
| New | +$17.5K |
|
|
RAPP
507
Rapport Therapeutics
RAPP
$1.96B
| $13.6K | ﹤0.01% |
+768
| New | +$17K |
|
508
Entrada Therapeutics
TRDA
$254M
| $13.6K | ﹤0.01% |
+785
| New | +$14.2K |
|
509
Humacyte
HUMA
$168M
| $13.6K | ﹤0.01% |
+2,685
| New | +$13.3K |
|
|
INN
510
Summit Hotel Properties
INN
$766M
| $13.4K | ﹤0.01% |
+1,953
| New | +$12.8K |
|
511
Keros Therapeutics
KROS
$197M
| $13.4K | ﹤0.01% |
+844
| New | +$43.9K |
|
|
MESO
512
Mesoblast
MESO
$1.83B
| $13.3K | ﹤0.01% |
+671
| New | +$7.43K |
|
|
PLYM
513
DELISTED
Plymouth Industrial REIT
PLYM
| $13.1K | ﹤0.01% |
+737
| New | +$14.6K |
|
514
Arbutus Biopharma
ABUS
$847M
| $13K | ﹤0.01% |
+3,979
| New | +$14.6K |
|
515
SITE Centers
SITC
$236M
| $13K | ﹤0.01% |
+850
| New | +$13.7K |
|
|
BCYC
516
Bicycle Therapeutics
BCYC
$269M
| $12.9K | ﹤0.01% |
+924
| New | +$19.8K |
|
517
Mineralys Therapeutics
MLYS
$2.32B
| $12.9K | ﹤0.01% |
+1,045
| New | +$13.7K |
|
|
GRAL
518
GRAIL Inc
GRAL
$2.72B
| $12.5K | ﹤0.01% |
+699
| New | +$11.4K |
|
|
GOOD
519
Gladstone Commercial Corp
GOOD
$623M
| $12.5K | ﹤0.01% |
+767
| New | +$12.7K |
|
520
Stoke Therapeutics
STOK
$1.84B
| $12.3K | ﹤0.01% |
+1,112
| New | +$13.7K |
|
521
Omeros
OMER
$845M
| $12K | ﹤0.01% |
+1,217
| New | +$8.35K |
|
522
Oric Pharmaceuticals
ORIC
$1.17B
| $12K | ﹤0.01% |
+1,482
| New | +$13.6K |
|
523
Phathom Pharmaceuticals
PHAT
$928M
| $11.7K | ﹤0.01% |
+1,436
| New | +$17.8K |
|
524
Annexon
ANNX
$796M
| $11.5K | ﹤0.01% |
+2,238
| New | +$13.8K |
|
525
Coinbase
COIN
$42.2B
| $11.2K | ﹤0.01% |
+45
| New | +$11.4K |
|
Similar funds
CM
BP
AAM
CAG
WHRC
RCG
AL
CGPCS
GF Fund Management's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for GF Fund Management, which disclosed 637 positions worth $4.62B. Its ten largest holdings account for 48% of the portfolio.
Its largest position is NVIDIA: 2,904,119 shares worth $390M.
By sector, the portfolio is most concentrated in Technology at 45% of assets, followed by Consumer Discretionary and Communication Services.
- GF Fund Management's largest Q4 2024 buy was NVIDIA: 2,904,119 shares worth $390M.
- GF Fund Management's ten largest holdings make up 48% of its $4.62B portfolio in Q4 2024.
- GF Fund Management disclosed 637 positions in Q4 2024, its first 13F filing on record.
Based on GF Fund Management's 13F filing for Q4 2024, filed 19 Feb 2025.